Esofag-L Capsule SR is a combination medication containing Levosulpiride 75 mg and Esomeprazole 40 mg, formulated for the management of gastrointestinal disorders characterized by dyspepsia, gastroesophageal reflux disease (GERD), and motility disturbances. Levosulpiride, a selective dopamine D2 receptor antagonist, enhances gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating associated with delayed gastric emptying and functional dyspepsia. Esomeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing symptomatic relief from acid-related mucosal damage, esophagitis, and reflux symptoms. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, optimizing symptom control and improving patient compliance. Esofag-L Capsule SR is indicated in adults for the treatment of GERD, erosive esophagitis, and functional dyspepsia with associated motility disorders. It should be used under medical supervision, with caution in patients with hepatic impairment or a history of hypersensitivity to either component. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances. Contraindications include known hypersensitivity to Levosulpiride, Esomeprazole, or other proton pump inhibitors. Regular monitoring and adherence to prescribed dosage are essential for optimal therapeutic outcomes.